[go: up one dir, main page]

CO2019009413A2 - Composiciones intencionalmente seleccionadas que comprenden cannabinoides purificados y/o terpenos purificados - Google Patents

Composiciones intencionalmente seleccionadas que comprenden cannabinoides purificados y/o terpenos purificados

Info

Publication number
CO2019009413A2
CO2019009413A2 CONC2019/0009413A CO2019009413A CO2019009413A2 CO 2019009413 A2 CO2019009413 A2 CO 2019009413A2 CO 2019009413 A CO2019009413 A CO 2019009413A CO 2019009413 A2 CO2019009413 A2 CO 2019009413A2
Authority
CO
Colombia
Prior art keywords
purified
cannabinoids
terpenes
compositions comprise
selected compositions
Prior art date
Application number
CONC2019/0009413A
Other languages
English (en)
Inventor
Kurt Levy
Jonathan Michael Cooper
Jonathan Reed Martin
Brian Geoffrey Reid
Original Assignee
Canopy Growth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/616,874 external-priority patent/US20170266153A1/en
Application filed by Canopy Growth Corp filed Critical Canopy Growth Corp
Publication of CO2019009413A2 publication Critical patent/CO2019009413A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/658Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)

Abstract

En este documento se divulgan nuevas composiciones que comprenden un cannabinoide purificado y un terpeno purificado. En una realización, las composiciones comprenden uno o más cannabinoides purificados. En una realización, las composiciones comprenden uno o más cannabinoides purificados en combinación con uno o más terpenos purificados. En una realización, las composiciones comprenden proporciones no naturales. En una realización, las composiciones comprenden concentraciones no naturales. En una realización, las composiciones comprenden efectos inesperados y/o sinérgicos.
CONC2019/0009413A 2017-03-01 2019-08-29 Composiciones intencionalmente seleccionadas que comprenden cannabinoides purificados y/o terpenos purificados CO2019009413A2 (es)

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US201762465688P 2017-03-01 2017-03-01
US201762469415P 2017-03-09 2017-03-09
US201762475153P 2017-03-22 2017-03-22
US201762477990P 2017-03-28 2017-03-28
US201762489360P 2017-04-24 2017-04-24
US201762490567P 2017-04-26 2017-04-26
US201762490465P 2017-04-26 2017-04-26
US201762491175P 2017-04-27 2017-04-27
US201762491160P 2017-04-27 2017-04-27
US201762491980P 2017-04-28 2017-04-28
US201762491899P 2017-04-28 2017-04-28
US201762509651P 2017-05-22 2017-05-22
US201762510229P 2017-05-23 2017-05-23
US201762510660P 2017-05-24 2017-05-24
US201762510672P 2017-05-24 2017-05-24
US201762511218P 2017-05-25 2017-05-25
US15/616,874 US20170266153A1 (en) 2015-02-27 2017-06-07 Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes
PCT/US2018/020440 WO2018160827A1 (en) 2017-03-01 2018-03-01 Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes

Publications (1)

Publication Number Publication Date
CO2019009413A2 true CO2019009413A2 (es) 2019-09-09

Family

ID=63370542

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0009413A CO2019009413A2 (es) 2017-03-01 2019-08-29 Composiciones intencionalmente seleccionadas que comprenden cannabinoides purificados y/o terpenos purificados

Country Status (10)

Country Link
EP (1) EP3589129A4 (es)
CN (1) CN110582206A (es)
AU (1) AU2018227544A1 (es)
BR (1) BR112019018088A2 (es)
CA (1) CA3054690A1 (es)
CO (1) CO2019009413A2 (es)
IL (1) IL268929A (es)
MX (1) MX2019010370A (es)
PE (1) PE20200383A1 (es)
WO (1) WO2018160827A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3031123C (en) 2018-01-23 2023-11-07 High Sierra Technologies, Inc. Cannabis products modified by removing volatile organic compounds and adding volatile unsaturated hydrocarbons
US12458906B2 (en) 2018-01-23 2025-11-04 High Sierra Technologies, Inc. Methods of modifying a naturally occurring cannabis raw plant material, a purified cannabis product from a naturally occurring cannabis raw plant material, and a modified cannabis product from a naturally occurring cannabis raw plant material
IL266151A (en) * 2019-04-18 2019-07-31 Kanabo Res Ltd Dilute for the cannabinoid preparations
CA3148236A1 (en) 2019-07-22 2021-01-28 Canopy Growth Corporation Continuous crystallization of cannabinoids in a stirred-tank reactor
EP4065105A4 (en) * 2019-11-26 2023-05-31 Lycored Ltd. ANTI-INFLAMMATORY SYNERGIC COMBINATIONS OF CANNABINOID AND LYCOPINE
AU2021264109A1 (en) * 2020-04-29 2022-12-08 Ligar Limited Partnership Imprinted polymers and methods for their use
CA3152633A1 (en) * 2020-07-27 2022-02-03 Canopy Growth Corporation Methods of synthesizing cannabielsoin and analogs thereof
WO2022165165A1 (en) * 2021-01-29 2022-08-04 The Johns Hopkins University Limonene effects on tetrahydrocannabinol (thc)-induced anxiety
CN113368086B (zh) * 2021-08-11 2021-12-03 龙麻(上海)医药研发有限责任公司 一种大麻素组合物及其在制备治疗帕金森、阿尔茨海默等神经退行性疾病的药物中的应用
WO2023245185A1 (en) * 2022-06-17 2023-12-21 New Growth Brands, Inc. Compositions comprising cannabinoids and methods of preparation and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009019322A1 (de) * 2009-04-30 2010-11-11 The Health Concept Gmbh Verfahren zur Herstellung von Synthetischen Cannabinoiden
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
TWI583374B (zh) * 2010-03-30 2017-05-21 Gw伐瑪有限公司 使用植物大麻素次大麻二酚(cbdv)來治療癲癇之用途
ES2784229T3 (es) * 2013-11-20 2020-09-23 Panag Pharma Inc Composiciones y procedimientos para el tratamiento de la inflamación y el dolor ocular
AU2016225026A1 (en) * 2015-02-27 2017-09-07 Canopy Growth Corporation Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral

Also Published As

Publication number Publication date
EP3589129A1 (en) 2020-01-08
MX2019010370A (es) 2019-10-22
BR112019018088A2 (pt) 2020-03-24
WO2018160827A1 (en) 2018-09-07
IL268929A (en) 2019-10-31
PE20200383A1 (es) 2020-02-24
EP3589129A4 (en) 2020-11-25
AU2018227544A1 (en) 2019-08-29
CN110582206A (zh) 2019-12-17
CA3054690A1 (en) 2018-09-07

Similar Documents

Publication Publication Date Title
CO2019009413A2 (es) Composiciones intencionalmente seleccionadas que comprenden cannabinoides purificados y/o terpenos purificados
MX2017010872A (es) Composiciones que comprenden combinaciones de cannabinoides purificados, con al menos uno de flavonoides, terpenos o minerales.
BR112017018276A2 (pt) ?composição que compreende peptidase e biotensoativo e seu uso?
CO2021005884A2 (es) Moduladores de la alfa-1 antitripsina
CO2018013557A2 (es) Composiciones que comprenden cepas bacterianas
CO2020001325A2 (es) Combinaciones herbicidas sinérgicas
CL2019001187A1 (es) Combinaciones fungicidas.
UY38032A (es) Oxadiazoles fungicidas
NI201900096A (es) Moduladores de la expresión de pcsk9
ECSP21026021A (es) Moduladores de la expresión de pnpla3
AR112015A1 (es) Composiciones sólidas para administración oral
AR113419A1 (es) Formulación aerosolizable
UY38284A (es) Composiciones y métodos para agonizar el receptor cb2
UY37342A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
CO2019000604A2 (es) Composición vaginal que comprende una combinación de estrógeno y vitamina d
CL2016003023A1 (es) “compuestos derivados de (bencil-piperazin-1-il)(tetrahidrofuran-carbonil o tetrahidropiran-carbonil) sustituido, moduladores rorg; composición farmacéutica que los comprende; y su uso en el tratamiento de la esclerosis múltiple y espondilitis anquilosante”. pct
MX2018007231A (es) Una composicion antimicrobiana.
SE1651620A1 (sv) A field emission light source adapted to emit UV light
CL2021001246A1 (es) Moduladores de expresión irf5.
MX2020010424A (es) Comprimido o composicion que contiene n-acil etanolamina y cannabinoides.
MX2023008764A (es) Composiciones y metodos para prevenir y tratar afecciones.
MX2018012377A (es) Composicion.
NI201900006A (es) Combinaciã“n de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacã‰uticas de ã‰stos
AR110663A1 (es) Composición que comprende fluido de reemplazo de hemoconcentración
CO2020003134A2 (es) Moduladores de la expresión de enac